PTNPALATIN TECHNOLOGIES INC

NYSE palatin.com


$ 2.03 $ -0.04 (-1.93 %)    

Thursday, 16-May-2024 15:58:59 EDT
QQQ $ 451.67 $ -1.79 (-0.39 %)
DIA $ 399.14 $ -0.14 (-0.04 %)
SPY $ 528.49 $ -1.29 (-0.24 %)
TLT $ 92.06 $ -0.04 (-0.04 %)
GLD $ 220.06 $ -0.83 (-0.38 %)
$ 2.07
$ 2.06
$ 0.00 x 0
$ 0.00 x 0
$ 2.03 - $ 2.13
$ 1.43 - $ 5.65
386,625
na
33.4M
$ 1.04
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-15-2024 03-31-2024 10-Q
2 02-14-2024 12-31-2023 10-Q
3 11-14-2023 09-30-2023 10-Q
4 09-28-2023 06-30-2023 10-K
5 05-15-2023 03-31-2023 10-Q
6 02-14-2023 12-31-2022 10-Q
7 11-14-2022 09-30-2022 10-Q
8 09-22-2022 06-30-2022 10-K
9 05-16-2022 03-31-2022 10-Q
10 02-14-2022 12-31-2021 10-Q
11 11-15-2021 09-30-2021 10-Q
12 09-28-2021 06-30-2021 10-K
13 05-14-2021 03-31-2021 10-Q
14 02-16-2021 12-31-2020 10-Q
15 11-16-2020 09-30-2020 10-Q
16 09-25-2020 06-30-2020 10-K
17 05-11-2020 03-31-2020 10-Q
18 02-10-2020 12-31-2019 10-Q
19 11-12-2019 09-30-2019 10-Q
20 09-12-2019 06-30-2019 10-K
21 05-09-2019 03-31-2019 10-Q
22 02-11-2019 12-31-2018 10-Q
23 11-09-2018 09-30-2018 10-Q
24 09-13-2018 06-30-2018 10-K
25 05-14-2018 03-31-2018 10-Q
26 02-12-2018 12-31-2017 10-Q
27 11-13-2017 09-30-2017 10-Q
28 09-25-2017 06-30-2017 10-K
29 05-15-2017 03-31-2017 10-Q
30 02-10-2017 12-31-2016 10-Q
31 11-14-2016 09-30-2016 10-Q
32 09-19-2016 06-30-2016 10-K
33 05-16-2016 03-31-2016 10-Q
34 02-12-2016 12-31-2015 10-Q
35 11-12-2015 09-30-2015 10-Q
36 09-18-2015 06-30-2015 10-K
37 05-12-2015 03-31-2015 10-Q
38 02-12-2015 12-31-2014 10-Q
39 11-14-2014 09-30-2014 10-Q
40 09-12-2014 06-30-2014 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-palatin-techs-maintains-17-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Palatin Techs (AMEX:PTN) with a Buy and maintains $17 price target.

 hc-wainwright--co-reiterates-buy-on-palatin-techs-maintains-17-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Palatin Techs (AMEX:PTN) with a Buy and maintains $17 price target.

 hc-wainwright--co-reiterates-buy-on-palatin-techs-maintains-17-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Palatin Techs (AMEX:PTN) with a Buy and maintains $17 price target.

 palatin-technologies-and-2-other-stocks-under-3-insiders-are-buying

The Dow Jones index closed slightly lower on Thursday. When insiders purchase or sell shares, it indicates their confidence or ...

 palatin-technologies-eyes-growing-6b-dry-eye-disease-market-with-late-stage-study-data

Palatin Technologies unveils Phase 3 PL9643 MELODY-1 trial results for dry eye disease treatment, showcasing statistically sign...

 palatin-announces-phase-3-pl9643-melody-1-dry-eye-disease-ded-clinical-data-results-presented-at-american-society-of-cataract-and-refractive-surgery-ascrs-2024

Palatin Technologies, Inc. (NYSE:PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that ...

 why-bumble-shares-are-trading-lower-by-12-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results.

 hc-wainwright--co-maintains-buy-on-palatin-techs-adjusts-price-target-to-17

HC Wainwright & Co. analyst Joseph Pantginis maintains Palatin Techs (AMEX:PTN) with a Buy, adjusts target to $17 from $70.

 palatin-technologies-disappointing-data-from-dry-eye-disease-study-stock-plummets

Palatin Technologies' results from PL9643 MELODY-1 Phase 3 trial for dry eye disease. The co-primary endpoints and secondar...

 dow-dips-200-points-tjx-posts-upbeat-sales

U.S. stocks traded lower this morning, with the Dow Jones index falling around 200 points on Wednesday. Following the market o...

 palatin-reports-results-of-pl9643-melody-1-pivotal-phase-3-clinical-trial-in-patients-with-dry-eye-disease-on-an-intent-to-treat-analysis-co-primary-sign-endpoint-and-secondary-sign-endpoints-not-met

On an Intent-to-Treat Analysis, Co-Primary Symptom Endpoint Met, Statistical Significance (P<0.025). PL9643 treatment for th...

 hc-wainwright--co-reiterates-buy-on-palatin-techs-maintains-70-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Palatin Techs (AMEX:PTN) with a Buy and maintains $70 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION